Muscular Dystrophy Canada fund nine new projects through 2023 grant program
NMD4C Investigators involved in many of these exciting clinical and translational research projects
On Thursday March 30th, Muscular Dystrophy Canada (MDC) announced the results of their 2023 Neuromuscular Clinical and Translational Research Grant Program. A dedicated Canadian source of funding for neuromuscular research, this annual funding competition invests in clinical and translational research projects related to the diagnosis, treatment, or clinical care of neuromuscular disorders. These research grants help fill current gaps in the funding landscape.
This year we are pleased to celebrate the many NMD4C investigators and members who are leading and supporting MDC-funded projects! You can find the full list of funded projects on MDC’s website.
2023 Clinical Research Projects
Establishing the Top Ten Research Priorities for Respiratory Care of Childhood Neuromuscular Disorders ($50,000)
NMD4C investigators and collaborators as project co-investigators and collaborators
Dietary Protein Requirements in Adults with Muscular Dystrophy ($100,000)
Project Lead
Dr Tyler Churchward-Venne
McGill University
NMD4C member as project co-investigator
Dr Mark Tarnopolsky
Muscle MRI in neuromuscular disorders. The era of Artificial Intelligence ($100,000)
NMD4C investigator as project collaborator
B-FIT! Taking exercise away from the hospital into the home environment in people with Oculopharyngeal muscular dystrophy ($100,000)
Project Lead
Dr Eric Voorn
University of Amsterdam
NMD4C investigators and members as project co-investigators and collaborators
Reimagining Rehabilitation for SMA: Patient and Family Perspectives ($83,166)
Project Lead
Dr Jill Glennis Zwicker
University of British Columbia
NMD4C investigators and members as project co-investigators and collaborators
Translational Research Grants
Therapy development for centronuclear myopathy caused by DNM2 gene changes ($100,000)
How genealogies (family histories) can help us understand myotonic dystrophy type 1 ($99,600)
Project Lead
Dr Simon Girard
Université du Québec à Chicoutimi
NMD4C investigators as project co-investigators
Evaluating the impact of stop variants on MLIP’s (Muscular LMNA-Interacting Protein) function in muscle ($100, 000)
Pre-clinical testing of novel pharmacological inhibitors of toxic DMPK mRNA in models of myotonic dystrophy type 1 ($100 000)
Project Lead
Dr Pascal Chartrand
University of Montreal
Read next...
National Training Standards Approved for AFC in Neuromuscular Medicine
The Royal College has approved the National Training Standards for the AFC in Neuromuscular Medicine, enabling PGME offices to apply for program accreditation. This milestone follows the discipline’s initial recognition in 2022.
Expanding National Clinical Outcome Assessment Capacity with Train(e)d
NMD4C and MDC have launched Train(e)d. This initiative is part of NMD4C’s broader efforts to build national capacity in outcome measures and natural history research in support of consistent and high-quality clinical assessments across Canada.
Announcing the 2025 Collaborative Research Training Award Recipients!!!
We are excited to announce the recipients of the 2025 NMD4C Collaborative Research Training Awards which supports Canadian trainees in their efforts to advance neuromuscular disease research while strengthening national collaboration among neuromuscular research laboratories.
NMD4C Hosts 2nd Annual Basic Research Summer School at York University!
The NMD4C is excited to announce a new program for neuromuscular research trainees that will support collaboration opportunities between Canadian research labs.
